111 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
in September 2022. The majority of traditional research and development expenses associated with PEDMARK® are now recorded as general and administrative
8-K
EX-10.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
(a) the right to exercise the majority of voting rights and other governance rights in respect of that body corporate, or (b) the ownership of a majority
424B7
xxm90e
15 Mar 24
Prospectus with selling stockholder info
3:53pm
8-K
EX-4.1
v7zz8z3jfreme
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
424B3
6q73dspnpu8aa7qwinnq
15 Dec 22
Prospectus supplement
5:12pm
8-K
EX-4.1
x3pvqhvhqet
26 Sep 22
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment
5:03pm
8-K
EX-4.1
8ixrk opv
22 Aug 22
Fennec Pharmaceuticals Closes First $5 Million Investment
9:00am